Novo Nordisk and Echosens Education Hub: Liver disease in the cardiometabolic patient: a guide to risk management in type 2 diabetes
| Thursday, August 21, 2025 |
| 1:15 PM - 2:00 PM |
| Exhibition Hall - Theatrette 1 |
Details
The link between type 2 diabetes (T2D) and the development & progression of metabolic dysfunction-associated fatty liver disease (MAFLD) to metabolic dysfunction-associated steatohepatitis (MASH), is well established. Moreover, T2D is independently associated with an increased risk of adverse hepatic outcomes including decompensated cirrhosis and hepatocellular carcinoma (HCC).
Local and international diabetes guidelines now recommend liver screening using non-invasive tests in all patients with type 2 diabetes as a part of complications assessment.
Join this practical multidisciplinary discussion with Prof James O’Beirne (Hepatologist) and Dr Sarah Parry (Endocrinologist) as they discuss how, when & why to implement liver screening in clinical practice. This interactive session will include practical case scenarios using guideline-recommended non-invasive tests such as fibrosis-4 (FIB-4) and vibration-controlled transient elastography (VCTE).
References
1. Loomba R, Abraham M, Unalp A, et al. Hepatology 2012; 56: 943-51. 59. 2. Huang DQ, Wilson LA, Behling C, et al. Gastroenterology 2023; 165: 463-472.e5. 3. Huang DQ, Noureddin N, Ajmera V, et al. Lancet Gastroenterol Hepatol 2023; 8: 829-836 4. 4. O'Beirne J, Skoien R, Leggett BA, et al. Med J Aust 2023; 219: 358-365. 5. Recommendations for the assessment of MAFLD in primary care: a consensus statement. GESA. 2024 6. Cusi et al. Diabetes Care. 2025 https://doi.org/10.2337/dci24-0094
Speaker
Professor James O'Beirne
Sunshine Coast University Hospital
Liver disease in the cardiometabolic patient: a guide to risk management in type 2 diabetes
Biography
Prof. O’Beirne is a Consultant Hepatologist at the Sunshine Coast University Hospital. He trained in Hepatology in the UK and was appointed as a Consultant Transplant Hepatologist at the Royal Free Hospital, London in 2007. Prof. O’Beirne relocated to Australia in 2017 to help develop the hepatology service at Sunshine Coast University Hospital.
Prof. O’Beirne is active in commercial and investigator led clinical studies in all aspects of hepatology. He is a member of the GESA liver faculty and the Baveno cooperation. He is currently hepatology editor for the IMJ and Associate editor for Frontline Gastroenterology.
Dr Sarah Parry
Endocrinologist
University of Sydney
Liver disease in the cardiometabolic patient: a guide to risk management in type 2 diabetes
Biography
Dr Sarah Parry MBBS PhD is a Staff Specialist Endocrinologist at Royal Prince Alfred Hospital, where she leads the Diabetes and Liver Clinic. Her PhD was titled “Non-alcoholic steatohepatitis with fibrosis in diabetes: clinical exploration and targeting CCN family members in a pre-clinical rodent model”. She is also passionate about medical education and is a Sydney Horizon Educator in the Metabolic Health Program at the University of Sydney and is involved in teaching programs with the Australian Diabetes Society.
